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Abstract
Different types of ionizing radiation produce different dependences of cancer risk on radiation dose/dose rate. Sparsely
ionizing radiation (e.g. c-rays) generally produces linear or upwardly curving dose responses at low doses, and the risk
decreases when the dose rate is reduced (direct dose rate effect). Densely ionizing radiation (e.g. neutrons) often produces
downwardly curving dose responses, where the risk initially grows with dose, but eventually stabilizes or decreases. When
the dose rate is reduced, the risk increases (inverse dose rate effect). These qualitative differences suggest qualitative
differences in carcinogenesis mechanisms. We hypothesize that the dominant mechanism for induction of many solid
cancers by sparsely ionizing radiation is initiation of stem cells to a pre-malignant state, but for densely ionizing radiation
the dominant mechanism is radiation-bystander-effect mediated promotion of already pre-malignant cell clone growth.
Here we present a mathematical model based on these assumptions and test it using data on the incidence of dysplastic
growths and tumors in the mammary glands of mice exposed to high or low dose rates of c-rays and neutrons, either with
or without pre-treatment with the chemical carcinogen 7,12-dimethylbenz-alpha-anthracene (DMBA). The model provides a
mechanistic and quantitative explanation which is consistent with the data and may provide useful insight into human
carcinogenesis.
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Introduction
Experimental investigation of the induction of pre-malignant
growths and tumors in laboratory animals exposed to various
carcinogens is a well-established method for gaining insight into
the mechanisms of carcinogenesis, from which better understand-
ing of cancer in humans can be achieved [1,2]. In particular,
different types of ionizing radiation produce different dependences
of cancer risk on radiation dose and dose rate. For radiation doses
which are sufficiently low to avoid substantial cell killing, sparsely
ionizing radiation, such as c-rays, generally produces dose
response shapes which are linear or with a positive second
derivative, e.g. upwardly curving linear-quadratic functions. When
the dose rate is reduced, i.e. the same dose is delivered over a
longer time, the risk generally decreases and the dose response
becomes a linear function of dose [3,4,5]. This is called a direct
dose rate effect. In contrast, densely ionizing radiations, such as
neutrons and a-particles, tend to produce dose response shapes
with a negative second derivative, i.e. downwardly curving, where
the risk initially grows with dose, but eventually reaches a plateau
and/or begins to decrease. When the dose rate is reduced, the risk
generally increases [6,7,8,9,10]. This is called an inverse dose rate
effect.
These qualitative differences in dose response shape and dose
rate dependences suggest qualitative differences in the mechanisms
of carcinogenesis by sparsely and densely ionizing radiation. Both
radiation types produce ionizing tracks, which consist of the highly
correlated ionizations and excitations produced by a single
incident photon, electron, neutron, or other particle within a very
short time. An ionizing track can damage biomolecules, e.g.
produce double strand breaks in DNA [11,12]. Damage can be
generated by each track which traverses a cell, and damage
produced by two (or more) different ionizing tracks can interact. If
such damage is not repaired correctly, it has the potential to
initiate the cell into a pre-malignant state, placing it on the path
towards eventual tumor formation.
The yield of incorrectly repaired damage from one-track action is
generallyproportionaltothenumberoftrackstraversingacell,i.e.to
the radiation dose. The damage yield from two-track action (i.e. due
to interactions of damage generated by two independent tracks) is
generally nonlinear (often quadratic) in dose. When the radiation
dose is delivered over a longer time period (i.e. when the dose rate is
reduced), traversals of the cell by ionizing tracks occur farther apart
in time. This allows for damage repair during irradiation and
reduces the probability that damage induced by a given track will
interact with damage induced by a subsequent track [12,13].
Consequently, one-track damage typically results in linear dose
responses with no dependence on dose rate, and two-track damage
typically results in quadratic dose responses which are reduced in
magnitude by reducing the dose rate – i.e. a direct dose rate effect.
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damaging to a cell than a track of sparsely ionizing radiation
[11,14]. Traversal by multiple tracks of sparsely ionizing radiation
is often required for accumulation of damage sufficient to initiate
(or kill) a cell. In contrast, initiation or clonogenic death can be
produced by only a few tracks (or even a single track) of densely
ionizing radiation [14]. Consequently, interaction of damage from
multiple tracks contributes substantially to carcinogenesis induced
by sparsely ionizing radiation, whereas densely ionizing radiation
induces cancers mainly through single-track action.
Because cells in a tissue communicate with each other through a
variety of signals, those cells which have not themselves been
traversed by ionizing tracks, but have received signals from cells
which have been traversed, can experience non-targeted effects of
radiation called radiation-bystander effects. Such effects include
altered differentiation, proliferation and migration, altered redox
balance and gene expression, cell death (e.g. apoptosis), as well as
various forms of genomic damage (e.g. micronuclei, mutagenesis,
chromosome damage) [15,16,17,18,19,20,21,22,23,24,25]. We
have suggested [7,26,27] that the radiation-bystander effect is
important for carcinogenesis induced by densely ionizing radiation
and may be (at least partially) responsible for the shape of the dose
response and for observed inverse dose-rate effects. In brief, we
assumed [27] that when a cell is traversed by an ionizing track, it
has some probability of being moved into an ‘‘activated’’ state, e.g.
a state of oxidative stress. Intercellular signals can propagate to
surrounding cells up to a considerable distance, and cause some of
those bystander cells, which have not been irradiated, to also
become activated. Eventually, the activated state reverts back to
the background state.
Because cell activation is a binary (‘‘on’’ or ‘‘off’’) phenomenon,
increasing the number of closely-timed ionizing track traversals
per cell beyond the number needed for activation will not increase
the activation probability, or the intensity of signals released to
surrounding cells. This explains saturation of bystander responses
as radiation dose is increased [17,28,29], which leads to
downwardly curving dose response curves (i.e. those with a
negative second derivative). Such dose response shapes tend to
produce inverse dose rate effects. This can be demonstrated by
mimicking a decrease in dose rate by splitting the dose into two
equal fractions [7,26]: If the dose response is linear (i.e. its second
derivative is zero), the sum of the responses to both fractions would
be the same as the response to the total dose – no dose rate effect.
If the dose response is upwardly curving (i.e. its second derivative is
positive), the sum of the responses to both fractions would be
smaller than the response to the total dose – a direct dose rate
effect. However, if the dose response is downwardly-curving (i.e. its
second derivative is negative), the sum of the responses to both
fractions would be greater than the response to the total dose – an
inverse dose rate effect.
As an example, suppose that one ionizing track traversal is
sufficient to activate a cell. If several track traversals occur within a
short time, the radiation-bystander effect will be the same as for
one traversal. However, if the dose rate is reduced so that the
average time between traversals becomes longer than the average
time needed for an activated cell to return back to the background
state, the duration of cell activation (and, hence, of the radiation-
bystander effect) will be prolonged, i.e. an inverse dose rate effect
will occur.
We hypothesize that the dominant mechanism for induction of
many solid cancers by sparsely ionizing radiation is direct damage
to stem cells, resulting in initiation of these cells to a pre-malignant
state, producing new (radiation-induced) pre-malignant cell clones.
Such clones can subsequently expand in cell number by
proliferation (promotion), and some cells within them can acquire
additional mutations to become fully malignant (transformation).
Finally, some of the transformed cells can eventually develop into
tumors (progression) [30,31,32]. In contrast, we hypothesize that
for densely ionizing radiation the dominant carcinogenesis
mechanism is indirect (radiation-bystander-effect mediated) pro-
motion of the growth of already existing pre-malignant cell clones.
Such clones were initiated by spontaneous processes, and/or
exposure to other agents (e.g. DMBA) that may initiate additional
clones which may not result in a substantially increased cancer risk
on their own, but can become activated by radiation-bystander
signals during irradiation. Activation can cause these clones to
increase in size, e.g. due to elevated proliferation rates, decreased
death/differentiation rates, and disrupted intercellular signaling.
This process results in radiation-bystander effect-mediated pro-
motion of the growth of pre-malignant cell clones, increasing the
subsequent risk of cancer at low doses, particularly when delivered
at low dose rates.
Here we present a mathematical model based on these
assumptions and test it using data on mammary carcinogenesis
(incidence of dysplastic growths and tumors in the mammary
glands) in mice exposed to high or low dose rates of c-rays and
neutrons, either with or without pretreatment with a low initiating
dose of the chemical carcinogen 7,12-dimethylbenz-alpha-anthra-
cene (DMBA). DMBA is metabolized into reactive compounds
which can produce potentially mutagenic and carcinogenic DNA
adducts [33,34,35], and ionizing radiation can damage DNA in
multiple ways, most importantly by the production of double
strand breaks (DSBs) [11,12,36,37]. Mechanisms similar to those
for mammary cancer may apply to other solid cancers, such as
those of the lung [38,39,40]. In contrast, leukemia may be driven
more by induction of specific radiation-induced cytogenetic effects
[41,42].
Results
The mechanistic mathematical model developed here is
consistent with the data for mouse mammary tumor and dysplasia
induction by three different carcinogens (c-rays, neutrons, and
DMBA), administered at different doses and dose rates (Figs. 1–2).
Notably, a single set of parameters was used for all the data. Best-
fit parameter values and parameter meanings are presented in
Table 1.
Tumors
The data for tumor induction by DMBA are consistent with a
linear dose response (Fig. 1) generated by the assumption that
DMBA is an initiating agent. As suggested by the value of the
DMBA-induced initiation parameter XDMBA (Table 1), each mgo f
this carcinogen is approximately as efficient at initiating mammary
tumors as 8 days of spontaneous initiation. The c-ray data are also
consistent with the interpretation that this radiation type acts as an
initiating agent, with a linear dose response at high dose rates. As
suggested by the value of parameter Xg, one Gy of high dose rate
c-radiation is approximately as efficient at initiating mammary
tumors as 1000 days of spontaneous initiation (Table 1). At lower
dose rates this efficiency is reduced due to repair of radiogenic
damage (which can cause initiation) during exposure. This direct
dose rate effect for c-rays can be seen in Fig. 1 and Fig. 2. For
example, when the dose rate is reduced to 0.01 Gy/day, the tumor
ERR is reduced by approximately an order of magnitude
compared with the highest tested dose rate of 576 Gy/day. Pre-
treatment of c-irradiated mice with 2.5 mg of DMBA has little
effect on increasing the predicted tumor ERR because initiating
Mechanistic Analysis of Radiation Carcinogenesis
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below. This is consistent with the data (Fig. 1). Of course, the
model fits to the data do not rule out promoting effects of DMBA
or c-rays, but such effects are probably not dominant.
For neutrons, however, the data are consistent with the
interpretation that this type of radiation acts mainly by
radiation-bystander effect mediated promotion, rather than by
initiation. Such an interpretation explains the following patterns
exhibited by the neutron data: (1) An inverse dose rate effect
(Figs. 1 and 3). (2) A dose response shape with a negative second
derivative (Fig. 1). (3) Synergistic (rather than additive) interactions
between neutrons and 2.5 mg of DMBA (Fig. 1), which are
Figure 1. The data and model predictions for mammary tumor ERR after c-ray, neutron and/or DMBA exposure. In the panels showing
effects of c-rays and neutrons, the legend is the same: HDR=high dose rate; LDR=low dose rate; DMBA=2.5 mg of DMBA. In this and the following
figures error bars represent 95% confidence intervals.
doi:10.1371/journal.pone.0028559.g001
Figure 2. Model predictions for tumor ERR/Gy as function of
dose/dose rate for c-rays and neutrons.
doi:10.1371/journal.pone.0028559.g002
Table 1. Best-fit model parameters for the excess relative risk
(ERR) of mammary tumors and dysplasias in mice treated with
DMBA and/or irradiated with c-rays and neutrons at high or
low dose rates.
Parameter Units Best-fit value 95% confidence interval
b days
21 1.40610
22 0.42610
22,2 . 3 610
22
d days
21 4.00610
24 2.1610
24, 5.7610
24
XDMBA days/mg 8.42 7.3, 11
Xg days/Gy 969 870, 1300
Krep days
21 0.391 0.36, 0.42
Yn days
21 2.51610
4 2.0610
4,3 . 8 610
4
q Gy/day 123 110, 150
L days 50 –
Parameter interpretations are: b=pre-malignant niche replication rate; d=the
parameter for homeostatic regulation of the number of pre-malignant cells per
niche; XDMBA and Xg=cell initiation constants for DMBA and c-rays;
Krep=constant for repair of c-ray-induced cell-initiating damage; Yn=neutron-
induced bystander promotion constant; q=radiation dose rate at which 50% of
all susceptible cells are activated by radiation-bystander signals under steady-
state conditions; L=lag time between the appearance of the first malignant cell
and tumor diagnosis.
doi:10.1371/journal.pone.0028559.t001
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which have been initiated by DMBA. These issues are discussed in
more detail below.
Dysplasias
Whereas tumors represent the final endpoint in the mammary
carcinogenic process, it was also possible to measure the incidence
of earlier-stage pre-malignant lesions following exposure to a low
initiating dose of 2.5 mg of DMBA, neutrons, or c-rays with or
without DMBA exposure one week prior to irradiation. These
studies used a model system that takes advantage of the fact that
mammary fat pads of 3-week-old mice from which the
rudimentary mammary tissue is removed and which, therefore,
contain no mammary cells of their own, serve as an ideal site for
the growth and differentiation of mammary cells into functional
mammary glands. As shown previously, pre-malignant cells can be
quantified by their expression as ductal dysplasias in mammary
outgrowths derived from carcinogen-treated mammary epithelium
[43,44]. Although the premalignant nature of these cells was found
to be a stable characteristic, the expression of their premalignant
state was found to be a function of the growth state of the
mammary outgrowth. During active growth and development (8–
10 weeks following injection of cells into the fat pad) the frequency
of dysplastic outgrowth was higher than when the outgrowth was
mature (16 weeks post injection). These results indicated that
expression of the premalignant phenotype is regulated through
interactions with the microenvironment. Acquisition of the
potential for autonomous growth by these pre-malignant cells
can be quantified by determining the frequency of persistent
lesions 16 weeks post-injection. As a result, both the induction of
premalignant cells (as total dysplasias measured 10 weeks post-
injection), and their subsequent dynamics (as persistent dysplasias
at 16 weeks post injection) can be quantified.
Results are shown in Fig. 3. Exposure to DMBA at a dose of
2.5 mg, which does not result in a substantial increase in the
frequency of mammary tumors (based on the best-fit parameter
values in Table 1, 2.5 mg of DMBA is approximately equivalent
to 20 days of spontaneous initiation, whereas 1 Gy of c-rays is
approximately equivalent to 1000 days), increased the frequency
of premalignant cells, but the large majority of these cells did not
acquire the potential for autonomous growth and the dysplastic
growths regressed. Similarly, exposure to c-rays with or without
prior exposure to DMBA resulted in an increase in premalignant
cells, but only a small fraction of these cells persisted. These
results are consistent with c-rays and DMBA as initiators with
very little, if any, impact on the promotion of initiated cells. In
contrast, exposure to a very low dose of neutrons increased both
the frequency and persistence of premalignant cells. This was
particularly dramatic following low dose rate exposures. Given
the low total dose (0.025 Gy) which would result in only a
fraction of the mammary cells being directly hit, these data
support a significant role for the radiation-bystander effect
(which, as our analysis suggests, acts mainly through promotion
of pre-malignant cell clone growth) in the neutron-induced
carcinogenic process.
Because the experimental procedure for measuring dysplasia
incidence was different from the procedure for measuring tumor
incidence (in the former case, cells from carcinogen-treated
animals were transplanted into untreated animals, whereas in the
latter case there was no such manipulation of the mammary
glands of treated animals), it is not surprising that there are some
systematic differences in the magnitudes of the dose responses for
tumors and dysplasias. In general, the ERRs for dysplasias were
approximately a factor of 1.5–2.0 lower than the ERRs for
tumors (see Figs. 1 and 4). We felt that this difference is not large
enough to warrant introducing a different parameter set for
dysplasias, and the ERR data for both tumors and dysplasias
were fitted together by the model using a single parameter set
presented in Table 1. Consequently, the best-fit predicted ERR
values for dysplasias tended to be somewhat higher than the data
points, due to influence from the tumor ERRs, but this difference
did not exceed the 95% confidence intervals of the data points
(Fig. 4).
Figure 3. Frequencies of ductal mammary dysplasias observed
in the fat pads of untreated mice after transplant of mammary
epithelial cells from carcinogen-treated mice. 1=control group,
2=treated with 2.5 mg DMBA, 3=0.25 Gy c-rays at high dose rate,
4=2.5 mg DMBA+0.25 Gy c-rays at high dose rate, 5=0.25 Gy c-rays at
low dose rate, 6=2.5 mg DMBA+0.25 Gy c-rays at low dose rate,
7=0.025 Gy neutrons at high dose rate, 8=2.5 mg DMBA+0.025 Gy
neutrons at high dose rate, 9=0.025 Gy neutrons at low dose rate,
10=2.5 mg DMBA+0.025 Gy neutrons at low dose rate. Filled bars=to-
tal dysplasias (measured 10 weeks after transplant), empty bars=per-
sistent dysplasias (those visible 16 weeks after transplant). Details are
discussed in the main text.
doi:10.1371/journal.pone.0028559.g003
Figure 4. The data and model predictions for dysplasia ERR
after exposure to c-rays, neutrons and/or DMBA. Legend:
DMBA=2.5 mg of DMBA; c=0.25 Gy of c-rays; n=0.025 Gy of neutrons;
HDR=high dose rate; LDR=low dose rate.
doi:10.1371/journal.pone.0028559.g004
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Goodness of fit of the model was estimated by the reduced X
2
method, which is defined as X
2 divided by the degrees of freedom.
A good fit is suggested by reduced X
2 near 1, whereas values .1
suggest a poor fit and values ,1 suggest overfitting. Using the
default model (Eqs. 3–4 in the Materials and Methods section),
which assumes that DMBA and c-rays are pure initiators and
neutrons are a pure promoter, the reduced X
2 was 1.35. If c-rays
were assumed to act as a promoter rather than as an initiator (i.e.
extending the neutron model to c-ray data), the reduced X
2
increased to 1.51. If neutrons were assumed to act as an initiator
rather than as a promoter (i.e. extending the c-ray model to
neutron data), the reduced X
2 increased even more to 2.55.
Discussion
Our analysis suggests that the neutron-induced risks of
mammary carcinogenesis for the selected mouse strain are
dominated by radiation-bystander effect-mediated promotion of
already pre-malignant cell clones. Initiation by neutrons of normal
cells into the pre-malignant state could not be ruled out, but was
not necessary for explaining the data. Modulation of the
promoting effects of radiation due to homeostatic regulation of
the average number of stem cells per niche (determined by
parameter d) was found to be important. This parameter was
responsible for preventing niches filled with pre-malignant cell
clones from becoming very large during irradiation by opposing
the proliferative promotion process. Consequently, the neutron
dose response shape became ‘‘flattened’’, i.e. had a negative
second derivative (Fig. 1).
Over time since exposure, a value of d.0 predicts that pre-
malignant niche sizes are gradually reduced towards the default
sizes set before irradiation, thereby reducing the ERR. This
suggests that homeostatic mechanisms in the organ oppose the
accumulation of dysplastic pre-malignant cells resulting in a
reduction in their number and/or carcinogeneic potential over
time after exposure. Such an interpretation is consistent with the
experimental data on pre-malignant mammary dysplasias: over
time since exposure many dysplastic lesions regress (Fig. 3). This
does not mean that those lesions which can no longer be observed
have been eliminated completely (in fact the persistence of such
occult initiated cells has been directly demonstrated previously
using the dysplasia model system [44]), but the number of pre-
malignant cells per lesion has probably been reduced. The
promotional effect of low dose rate neutron exposure opposes the
homeostatic mechanisms, causing the proportion of dysplasias
which persist to increase (Fig. 3).
The explanation for neutron-induced mammary tumor risk
suggested by our model, which is based on radiation-bystander
effect-mediated promotion, also provides a description for the
inverse dose rate effect seen clearly in the analyzed data (i.e. that
tumor risk per unit dose is higher at dose rates of 0.01 Gy/day
compared with higher dose rates). In essence, in a radiation-
bystander promotion-driven model the total duration of irradia-
tion, which varies inversely with dose rate, is the major
determinant of risk. Qualitatively, the conclusions drawn from
this analysis are the same as those presented previously in analyses
of radon-induced lung cancer risks in rats and humans [38,39,40],
possibly because densely ionizing radiation such as a-particles
emitted by radon and its progeny and neutrons may have
qualitatively similar biological effects.
In contrast with the dose responses seen with neutron exposure,
c-rays in the same mouse strain produce a relatively linear dose
response in the dose range up to 0.5 Gy. Instead of an inverse dose
rate effect, a direct dose rate effect is seen, as expected for sparsely
ionizing radiation. As mentioned previously, these differences in
the data suggest that the carcinogenesis mechanisms are very
different for neutrons vs. c-rays: the radiation-bystander effect is
probably very important for the former, and not (or less) important
for the latter.
When DMBA and c-rays are combined, additive effects from
these initiators are expected. However, when DMBA and neutrons
are combined, a synergistic interaction is expected because
neutrons can promote the growth of pre-malignant clones initiated
by DMBA. This is consistent with the data for both tumors (Fig. 1)
and dysplasias (Fig. 3). For example, the combination of 2.5 mg
DMBA and low dose rate neutrons produced substantially higher
tumor ERRs than the same doses of low dose rate neutrons alone
(Fig. 1): at 0.025 Gy of low dose rate neutrons the tumor ERR was
1.6 without DMBA and 3.1 with DMBA, at 0.05 Gy it was 2.2
and 3.7, and at 0.1 Gy it was 2.5 and 4.5, respectively. For high
dose rate neutrons, where the promoting effect per given dose
would be reduced because of reduced duration of exposure, the
interaction of neutrons with DMBA was less noticeable: at
0.025 Gy of high dose rate neutrons the tumor ERR was 0.5
without DMBA and 1.0 with DMBA, at 0.05 Gy it was 1.1 and
1.6, and at 0.1 Gy it was 1.4 and -0.7, respectively. Error bars for
these estimates are shown in Fig. 1. A qualitatively similar pattern
was observed for the frequency of persistent dysplasias (those
present at 16 weeks post-injection). At 0.025 Gy of low dose rate
neutrons the persistent dysplasia frequency was 25.5% without
DMBA and 35.4% with 2.5 mg DMBA, and for high dose rate
neutrons the respective frequencies were 12.5% and 18.9%. Error
bars are shown in Fig. 3. For c-rays, at either high or low dose
rate, combination with DMBA had only small effects on tumor
ERR or dysplasia frequency (Figs. 1 and 3).
In summary, the analysis presented here provided a mechanistic
quantitative model based on the hypothesis that carcinogens such
as DMBA and c-rays act mainly as initiators of pre-malignant
cells, whereas neutrons act mainly to promote the growth of
already existing pre-malignant cell clones. The model was then
directly tested using data for mammary carcinogenesis as well as
early events in the carcinogenic process induced by DMBA, c-rays
and neutrons in a well-established mouse mammary cancer animal
model. Importantly, the results support other evidence [38,39,40]
suggesting that densely ionizing radiation, such as neutrons and a-
particles, induces cancer mainly through promoting effects on pre-
malignant cell clones. Such promoting effects may occur due to
disruption of intercellular signaling by radiation, which can
happen even if only a small fraction of the cells are actually
traversed by ionizing tracks.
Materials and Methods
Model used
We previously assumed [27] that a susceptible cell (e.g. a
mammary stem cell) will have a probability Pa of being in the
activated bystander state, rather than in the background bystander
state, with Pa described by the following differential equation:
dPa=dt~c2S 1{Pa ðÞ {c3Pa ð1Þ
Here S is the average concentration of the bystander signal(s) in
the target organ, c2 determines cell activation (units=time
216
concentration
21), and c3 determines the opposite process, i.e. cell
deactivation back to the background state (units=time
21). The
term c2 S represents our assumption that the probability per unit
time of converting a cell from the background state to the activated
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The term 12Pa indicates the probability that the given cell has not
yet undergone this transition and that it is only such cells that are
available for being activated. This term thus describes the
‘‘saturation’’ phenomenon characteristic of radiation-bystander
responses (e.g. [28,29]). Finally, the term 2c3 Pa represents the
assumption that the activated state tends to spontaneously revert to
background at a fixed probability per unit time.
In the present paper we again use Eq. 1. We assume here that
the time-average over a short time of the signal concentration, S,
rapidly reaches a steady-state value in the target organ [45], which
is linearly proportional to the radiation dose rate, R. This
assumption can be derived from the plausible supposition that
each cell traversed by an ionizing track sends out the bystander
signal briefly. During protracted irradiation, cells throughout the
organ are hit at random continually. Thus, at any location the
time average of S over a characteristic relaxation time Tc (i.e. the
time needed to revert from the activated state to the background
state, Tc=1/c3) is spatially and time independent (after the initial
and before the final transients, which are assumed to be short), and
is proportional to R.
This assumption would be less likely to hold at very high dose
rates, where most or all cells are traversed by ionizing tracks at
least once per relaxation time (Tc). However, at such high dose
rates, essentially all cells susceptible to activation by bystander
signals would be activated (Pa=1), so any deviation of the
dependence of signal concentration on dose rate from linearity
(e.g. saturation of signal production) would not affect model
predictions. At low dose rates, where each individual cell would be
expected to be traversed at most once per relaxation time,
differences in dose rate would not matter to this particular cell.
However, the group of many cells communicating through
bystander signaling, which is the radiation ‘‘target’’ under our
assumptions, would be traversed by several tracks per relaxation
time even at quite low dose rates, so dependence of the group
response on dose rate is expected.
The assumed linear dependence of the steady-state bystander
signal concentration on radiation dose rate can be represented
mathematically by the function S=r R, where r is a proportion-
ality constant (units=time6concentration6dose
21). Defining a
new parameter k1=c2 r (units=dose
21), Eq. 1 can thus be
rewritten as follows: dPa/dt=c2 r R (12Pa)2c3 Pa=k1 R
(12Pa)2c3 Pa. An analytic solution for this expression is available.
However, to simplify the final model, it is possible to approximate
by using the equilibrium condition dPa/dt=0, and solving for Pa.
To reduce the number of adjustable parameters, we introduce a
new parameter q (=c 3/k1, units=dose6time
21), interpreted as the
radiation dose rate at which 50% of all susceptible cells are
activated under steady-state conditions. Given these assumptions
and manipulations, the equilibrium value of Pa is:
Pe~1= 1zq=R ðÞ ð 2Þ
The adjustable parameter q is determined by multiple factors
such as bystander signal range (which affects k1) and cell turnover
rate (which affects c3). If q is small, Pe approaches saturation (unity)
at lower dose rates than when q is large. Under background
conditions without excess radiation exposure, Pe=0.
The assumptions and mathematical implementation of our
carcinogenesis model were described in detail in previous papers
[46,47]. Briefly, the model uses a two-stage approach similar to the
classic two-stage clonal expansion model [8,48,49], where normal
stem cells can be initiated into a pre-malignant state, either
spontaneously or by radiation. A surviving initiated cell can grow
into a pre-malignant clone, which quickly takes over the stem cell
niche [50,51,52,53,54,55,56,57] or tissue compartment (e.g. a
colonic crypt) in which it originated. Niche boundaries initially
constrain further growth of the clone, so once the initial niche is
filled, clonal expansion proceeds by a much slower process of pre-
malignant niche replication or invasion and takeover of adjacent
normal niches by pre-malignant cells [57,58,59,60,61]. This slow
process occurs on the scale of multiple years and decades in
humans (and months in mice), and may involve acquisition of new
mutations [62]. Each pre-malignant cell in any niche has some
probability of transforming into a fully malignant cell and, after
some lag time (L), into a tumor [8,48,49]. The per-cell probability
of malignant transformation decreases with the age of the
individual, e.g. due to reduced stem cell proliferation and self-
renewal rates, reduced background malignant transformation
rates, and/or elevated death rates [63,64,65,66,67].
The mathematical expression for the excess relative risk (ERR)
of cancer following irradiation was derived previously: see Eq. 15
in [46]. For a single radiation exposure which occurs in a
sufficiently short time for cell proliferation to be neglected, this
expression can be simplified: see Eq. 2 in [68]. If the radiation dose
is sufficiently small for cell killing to be neglected, as can be done
for the experimental data analyzed here where the maximum c-
ray dose was 0.5 Gy and the maximum neutron dose was 0.1 Gy,
further simplification is possible and the ERR is given by:
ERR~ Q1Q2zQ3 ðÞ =Q4 ½  {1, where : ð3Þ
Q1~
1zYv
1zYv 1{exp {d A{Tx{L ðÞ ½  ðÞ ½ 
;
Q2~exp bA {Tx{L ðÞ ½  exp bT x ½  {1zbX v ðÞ ;
Q3~exp bA {Tx{L ðÞ ½  {1; Q4~exp bA {L ðÞ ½  {1
Here A is the age, Tx is the time at exposure, L is the lag time
between the appearance of the first malignant cell and tumor
diagnosis, b is pre-malignant niche replication rate (uni-
ts=time
21), d is the parameter for homeostatic regulation of the
number of pre-malignant cells per niche (units=time
21), Xv is the
term for initiation of new pre-malignant cells/clones (units=time),
and Yv is the term for promotion of already pre-malignant cell
clones (units=dimensionless).
The functions Xv and Yv are given by the following expressions:
Xv~XDMBADDMBAzXgDgG, ð4Þ
where G~2Rg
2 exp{KrepDg
 
Rg
  
{1zKrepDg
 
Rg
    
KrepDg
   2 hi
Yv~YnDn=RnPe~YnDn= Rnzq ðÞ
Here DDMBA, Dg and Dn are the doses for DMBA, c-rays and
neutrons, respectively, Rg and Rn are the dose rates, XDMBA and Xg
are cell initiation constants for DMBA and c-rays (units=time6
dose
21), Krep is the constant for repair of c-ray-induced cell-
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21), Yn is the neutron-induced
bystander promotion constant (units=time
21), and q is the
radiation dose rate at which 50% of all susceptible cells are
activated by radiation-bystander signals under steady-state condi-
tions. G is the Lea-Catcheside factor for repair of radiation-
induced damage for exposures at constant dose rate [69]. This
functional form is very commonly used to describe radiation
protraction and fractionation effects. Pe is the equilibrium value of
the cell activation probability, taken from Eq. 1. As discussed
above, the functional forms for Xv and Yv reflect our assumptions
that: (1) DMBA acts exclusively as an initiating agent; (2) c-
radiation also acts exclusively as an initiating agent, and the
initiating damage it causes is subject to repair; (3) neutrons act
exclusively as a promoting agent through radiation-bystander
effect-mediated mechanisms.
Data sets and model fitting procedure
The data on mammary tumors and dysplasias in female BALB/
C mice were accumulated by the Ullrich laboratory as previously
described [43,44]. For tumor induction, the mice were exposed to
the following carcinogens at the age of 12 weeks (84 days): (1) c-ray
doses up to 0.5 Gy, at a low dose rate of 0.01 Gy/day or at a high
dose rate up to 0.4 Gy/min (576 Gy/day); (2) fission-spectrum
neutron doses up to 0.1 Gy, at a low dose rate of 0.01 Gy/day or
at a high dose rate up to 0.25 Gy/min (360 Gy/day); (3) 7,12-
dimethylbenz-alpha-anthracene (DMBA) doses up to 75 mg; (4)
combinations of 2.5 mg DMBA with high- or low-dose rate c-rays
or neutrons, with the DMBA given 1 week prior to irradiation.
These carcinogen doses were not high enough to produce acute
lethality in the mice. Mammary tumor incidences were measured
up to the age of 800 days. A total of 3775 mice were used in these
tumorigenesis experiments, with 285 mice in the control group,
390 mice exposed to DMBA, 1560 exposed to c-rays, 338 exposed
to combinations of DMBA and c-rays, 590 exposed to neutrons,
and 612 exposed to combinations of DMBA and neutrons. Mice
were maintained in specific-pathogen-free conditions at the
AAALAC-approved Laboratory Animal Resource facility at
Colorado State University. All animal work was approved by the
Institutional Animal Care and Use Committee at Colorado State
University.
For dysplasia induction, mice were irradiated with 0.25 Gy c-
rays (high- or low-dose rate), or 0.025 Gy of neutrons (high- or
low-dose rate), and/or treated with 2.5 mg DMBA. Epithelial cells
were removed from the mammary glands of irradiated mice 16
weeks after exposure, and transplanted into fat pads of
unirradiated recipient mice, which have previously been cleared
of mammary tissue. The total number of ductal dysplasias, which
is a surrogate for the total number of pre-malignant stem cells, was
measured 10 weeks after transplantation, and the number of such
dysplasias which persist for longer time was measured 16 weeks
after transplantation. A total of 966 mice were used in these
dysplasia experiments, with 93 mice in the control group, 96 mice
exposed to DMBA, 195 exposed to c-rays, 199 exposed to
combinations of DMBA and c-rays, 194 exposed to neutrons, and
189 exposed to combinations of DMBA and neutrons.
The measured incidences of mammary tumors and total
frequency of dysplasias after each exposure scenario were
converted to excess relative risks (ERR). Fitting of the model to
the ERRs was carried out using a customized random-restart
simulated annealing algorithm implemented in the FORTRAN
language, using standard inverse variance weighting. A single
parameter set was used for both tumors and dysplasias. The
parameters were freely adjustable, with only non-negativity
constraints. The delay period between appearance of the first
malignant cell and detectable cancer was assumed to be L=50
days, and exploratory calculations showed that the predictions are
not very sensitive to this parameter. Ninety-five percent confidence
intervals for all adjustable parameters were estimated by
generating multiple synthetic data sets based on the experimental
data set and fitting the model to these synthetic data sets. The
simulated data sets were produced using the data points assuming
the normal distribution.
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